Masayo Shamoto-Nagai
Overview
Explore the profile of Masayo Shamoto-Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P
J Neural Transm (Vienna)
. 2024 Dec;
132(3):387-406.
PMID: 39621110
Monoamine oxidase catalyzes oxidative deamination of monoamine transmitters and plays a critical role in the pathogenesis of neuropsychiatric diseases. Monoamine oxidase is classified into type A and B (MAO-A, MAO-B)...
2.
Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P
J Neural Transm (Vienna)
. 2024 Jan;
131(6):639-661.
PMID: 38196001
Parkinson's disease is characterized by its distinct pathological features; loss of dopamine neurons in the substantia nigra pars compacta and accumulation of Lewy bodies and Lewy neurites containing modified α-synuclein....
3.
Naoi M, Maruyama W, Shamoto-Nagai M
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232361
Synucleinopathies are a group of neurodegenerative disorders caused by the accumulation of toxic species of α-synuclein. The common clinical features are chronic progressive decline of motor, cognitive, behavioral, and autonomic...
4.
Naoi M, Maruyama W, Shamoto-Nagai M
J Neural Transm (Vienna)
. 2021 Oct;
129(5-6):737-753.
PMID: 34654977
Parkinson's disease is characterized by typical motor symptoms, loss of dopamine neurons in the substantia nigra, and accumulation of Lewy body composed of mutated α-synuclein. However, now it is considered...
5.
Naoi M, Maruyama W, Shamoto-Nagai M
J Neural Transm (Vienna)
. 2020 Jan;
127(2):131-147.
PMID: 31993732
Parkinson's disease has been considered as a motor neuron disease with dopamine (DA) deficit caused by neuronal loss in the substantia nigra, but now proposed as a multi-system disorder associated...
6.
Naoi M, Wu Y, Shamoto-Nagai M, Maruyama W
Int J Mol Sci
. 2019 May;
20(10).
PMID: 31108962
In aging and neurodegenerative diseases, loss of distinct type of neurons characterizes disease-specific pathological and clinical features, and mitochondria play a pivotal role in neuronal survival and death. Mitochondria are...
7.
Shamoto-Nagai M, Hisaka S, Naoi M, Maruyama W
J Clin Biochem Nutr
. 2018 Jun;
62(3):207-212.
PMID: 29892158
Recently, toxic α-synuclein oligomer, which can mediate cell-to-cell propagation is suggested to cause sporadic Parkinson disease. α-Synuclein interacts with membrane lipids especially polyunsaturated fatty acids to stabilize its three-dementional structure....
8.
Naoi M, Maruyama W, Shamoto-Nagai M
J Neural Transm (Vienna)
. 2017 Dec;
125(11):1635-1650.
PMID: 29279995
Type A and B monoamine oxidases (MAO-A, -B) mediate and modulate intracellular signal pathways for survival or death of neuronal cells. MAO-A is associated with development of neuronal architecture, synaptic...
9.
Naoi M, Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W
J Neural Transm (Vienna)
. 2017 Oct;
124(12):1515-1527.
PMID: 29030688
Bioactive compounds in food and beverages have been reported to promote health and prevent age-associated decline in cognitive, motor and sensory activities, and emotional function. Phytochemicals, a ubiquitous class of...
10.
Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W, Naoi M
J Neural Transm (Vienna)
. 2017 Jun;
124(9):1055-1066.
PMID: 28577058
Type B monoamine oxidase (MAO-B) in glial cells has been considered to be associated with neuronal death in Parkinson's disease. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neurons in animal...